ReviewNature reviews. Drug discovery2017
Applications of chemogenomic library screening in drug discovery.
Review in Nature reviews. Drug discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed.
- New hit compounds againstAntimicrobial agents and chemotherapy · 2026Article
- AI-Driven Drug Discovery: Focus on Targets for Solid Tumors.Pharmaceutics · 2026Review
- Building a credibility-based framework for target discovery: Perspectives from tRNA synthetase-linked metabolic diseases.Briefings in bioinformatics · 2026Article
- CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability.Journal of pharmaceutical analysis · 2026Review
- Target agnostic cellular screening in the era of chemically induced proximity.RSC medicinal chemistry · 2025Review
- Comparative Profiling and Chemogenomics Application of Chemical Tools for NR4A Nuclear Receptors.Journal of medicinal chemistry · 2025Article
- Functional aptamer evolution-enabled elucidation of a melanoma migration-related bioactive epitope.Acta pharmaceutica Sinica. B · 2025Article
- Monensin Suppresses Multiple Features of House Dust Mite-Induced Experimental Asthma in Mice.Inflammation · 2025Article
- Chemogenomics for steroid hormone receptors (NR3).Communications chemistry · 2025Article
- Uncovering Novel Drugs that Restore Vision Using Orthogonal Pooling in Zebrafish.Advances in experimental medicine and biology · 2025Article
- Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.Acta pharmaceutica Sinica. B · 2024Review
- Ube3a unsilencer for the potential treatment of Angelman syndrome.Nature communications · 2024Article
- Chemogenomics for NR1 nuclear hormone receptors.Nature communications · 2024Article
- TTD: Therapeutic Target Database describing target druggability information.Nucleic acids research · 2024Article
- Fluorescent Reporter Systems to Investigate Chromatin Effector Proteins in Living Cells.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics.Current pharmaceutical biotechnology · 2024Review
- Integrating inflammatory biomarker analysis and artificial-intelligence-enabled image-based profiling to identify drug targets for intestinal fibrosis.Cell chemical biology · 2023Article
- Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity.ACS omega · 2023Article
- AMMVF-DTI: A Novel Model Predicting Drug-Target Interactions Based on Attention Mechanism and Multi-View Fusion.International journal of molecular sciences · 2023Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The allure of phenotypic screening, combined with the industry preference for target-based approaches, has prompted the development of innovative chemical biology technologies that facilitate the identification of new therapeutic targets for accelerated drug discovery. A chemogenomic library is a collection of selective small-molecule pharmacological agents, and a hit from such a set in a phenotypic screen suggests that the annotated target or targets of that pharmacological agent may be involved in perturbing the observable phenotype. In this Review, we describe opportunities for chemogenomic screening to considerably expedite the conversion of phenotypic screening projects into target-based drug discovery approaches. Other applications are explored, including drug repositioning, predictive toxicology and the discovery of novel pharmacological modalities.
Indexed as
Identifiers
28104905What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.